Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs

Autores
Dib, Alicia; Paredes, Alejandro Javier; Eliópulos, Natasha; Farias, Cristina Elena; Suárez, Gonzalo; Aldrovandi, Ariel; Palma, Santiago Daniel; Allemandi, Daniel Alberto; Lanusse, Carlos Edmundo; Sanchez Bruni, Sergio Fabian
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of this study was to evaluate the influence of different matrices developers on the pharmacokinetic behavior of Ricobendazole (RBZ) controlled release (CR) formulations and test their correlation in vitro-in vivo, using one Albendazole (ABZ)-based and one RBZ-based immediate-release formulation as references. The main excipients used for CR formulations were Hydroxypropyl Methyl Cellulose, Cetyl Alcohol, Gelucire 50/02® and Alginic Acid. Pharmacotechnical quality control tests were successfully completed. Twelve parasite-free no pregnant dogs were randomly divided into six groups and received different treatments (single oral doses) using an incomplete block design (two phases) (n=4). Phase I: treatment "A" (ABZ-based immediate-release formulation [25 mg/kg]). Treatment "B" (RBZ-based immediate release formulation [20 mg/kg]) and treatments from "C" to "F" (CR formulations [20 mg/kg]). Phase II was performed after 21 days of washout period. Blood samples were collected over 48 h and analysed by UV High Performance Liquid Chromatography. In vitro dissolution profiles showed that matrices agents favored a reservoir effect. Active metabolite Albendazole sulphoxide (ABZSO) or Ricobendazole (RBZ) plasma exposure measured in terms of area under concentration vs time curve (AUC) of all RBZ formulations was greater (p<0,05) when compared with that obtained for ABZ reference formulation. No statistical differences in AUC values were found among all RBZ formulations assayed (p>0.05). Nevertheless, RBZ-Cetyl alcohol formulation showed a statistical difference on its time peak concentration (p<0.05). In conclusion the results obtained in vitro do not correlate with those obtained in vivo, being this work useful to identify other matrices developers in RBZ-CR formulations.
Fil: Dib, Alicia. Universidad de la República; Uruguay
Fil: Paredes, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Eliópulos, Natasha. Universidad de la República; Uruguay
Fil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Suárez, Gonzalo. Universidad de la República; Uruguay
Fil: Aldrovandi, Ariel. Universidad de la República; Uruguay
Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Allemandi, Daniel Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Materia
BENZIMIDAZOLES
CANINES
ANTHELMINTICS
MATRICES DEVELOPERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/62956
Acceder
id CONICETDig_05e0984a130ac8f88e0b999521faaea7
oai_identifier_str oai:ri.conicet.gov.ar:11336/62956
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in DogsDib, AliciaParedes, Alejandro JavierEliópulos, NatashaFarias, Cristina ElenaSuárez, GonzaloAldrovandi, ArielPalma, Santiago DanielAllemandi, Daniel AlbertoLanusse, Carlos EdmundoSanchez Bruni, Sergio FabianBENZIMIDAZOLESCANINESANTHELMINTICSMATRICES DEVELOPERShttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4The aim of this study was to evaluate the influence of different matrices developers on the pharmacokinetic behavior of Ricobendazole (RBZ) controlled release (CR) formulations and test their correlation in vitro-in vivo, using one Albendazole (ABZ)-based and one RBZ-based immediate-release formulation as references. The main excipients used for CR formulations were Hydroxypropyl Methyl Cellulose, Cetyl Alcohol, Gelucire 50/02® and Alginic Acid. Pharmacotechnical quality control tests were successfully completed. Twelve parasite-free no pregnant dogs were randomly divided into six groups and received different treatments (single oral doses) using an incomplete block design (two phases) (n=4). Phase I: treatment "A" (ABZ-based immediate-release formulation [25 mg/kg]). Treatment "B" (RBZ-based immediate release formulation [20 mg/kg]) and treatments from "C" to "F" (CR formulations [20 mg/kg]). Phase II was performed after 21 days of washout period. Blood samples were collected over 48 h and analysed by UV High Performance Liquid Chromatography. In vitro dissolution profiles showed that matrices agents favored a reservoir effect. Active metabolite Albendazole sulphoxide (ABZSO) or Ricobendazole (RBZ) plasma exposure measured in terms of area under concentration vs time curve (AUC) of all RBZ formulations was greater (p<0,05) when compared with that obtained for ABZ reference formulation. No statistical differences in AUC values were found among all RBZ formulations assayed (p>0.05). Nevertheless, RBZ-Cetyl alcohol formulation showed a statistical difference on its time peak concentration (p<0.05). In conclusion the results obtained in vitro do not correlate with those obtained in vivo, being this work useful to identify other matrices developers in RBZ-CR formulations.Fil: Dib, Alicia. Universidad de la República; UruguayFil: Paredes, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Eliópulos, Natasha. Universidad de la República; UruguayFil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Suárez, Gonzalo. Universidad de la República; UruguayFil: Aldrovandi, Ariel. Universidad de la República; UruguayFil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Allemandi, Daniel Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; ArgentinaFil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaFil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; ArgentinaOMICS International2015-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/62956Dib, Alicia ; Paredes, Alejandro Javier; Eliópulos, Natasha; Farias, Cristina Elena; Suárez, Gonzalo; et al.; Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs; OMICS International; Clinical & Experimental Pharmacology; 5; 6; 12-2015; 1-82161-1459CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4172/2161-1459.1000198info:eu-repo/semantics/altIdentifier/url/https://www.omicsonline.org/open-access/pharmacokinetic-assessment-of-novel-controlled-release-formulations-ofricobendazole-intended-for-oral-administration-in-dogs-2161-1459-1000198.php?aid=64163info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:55:52Zoai:ri.conicet.gov.ar:11336/62956instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:55:52.38CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
title Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
spellingShingle Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
Dib, Alicia
BENZIMIDAZOLES
CANINES
ANTHELMINTICS
MATRICES DEVELOPERS
title_short Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
title_full Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
title_fullStr Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
title_full_unstemmed Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
title_sort Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
dc.creator.none.fl_str_mv Dib, Alicia
Paredes, Alejandro Javier
Eliópulos, Natasha
Farias, Cristina Elena
Suárez, Gonzalo
Aldrovandi, Ariel
Palma, Santiago Daniel
Allemandi, Daniel Alberto
Lanusse, Carlos Edmundo
Sanchez Bruni, Sergio Fabian
author Dib, Alicia
author_facet Dib, Alicia
Paredes, Alejandro Javier
Eliópulos, Natasha
Farias, Cristina Elena
Suárez, Gonzalo
Aldrovandi, Ariel
Palma, Santiago Daniel
Allemandi, Daniel Alberto
Lanusse, Carlos Edmundo
Sanchez Bruni, Sergio Fabian
author_role author
author2 Paredes, Alejandro Javier
Eliópulos, Natasha
Farias, Cristina Elena
Suárez, Gonzalo
Aldrovandi, Ariel
Palma, Santiago Daniel
Allemandi, Daniel Alberto
Lanusse, Carlos Edmundo
Sanchez Bruni, Sergio Fabian
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv BENZIMIDAZOLES
CANINES
ANTHELMINTICS
MATRICES DEVELOPERS
topic BENZIMIDAZOLES
CANINES
ANTHELMINTICS
MATRICES DEVELOPERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv The aim of this study was to evaluate the influence of different matrices developers on the pharmacokinetic behavior of Ricobendazole (RBZ) controlled release (CR) formulations and test their correlation in vitro-in vivo, using one Albendazole (ABZ)-based and one RBZ-based immediate-release formulation as references. The main excipients used for CR formulations were Hydroxypropyl Methyl Cellulose, Cetyl Alcohol, Gelucire 50/02® and Alginic Acid. Pharmacotechnical quality control tests were successfully completed. Twelve parasite-free no pregnant dogs were randomly divided into six groups and received different treatments (single oral doses) using an incomplete block design (two phases) (n=4). Phase I: treatment "A" (ABZ-based immediate-release formulation [25 mg/kg]). Treatment "B" (RBZ-based immediate release formulation [20 mg/kg]) and treatments from "C" to "F" (CR formulations [20 mg/kg]). Phase II was performed after 21 days of washout period. Blood samples were collected over 48 h and analysed by UV High Performance Liquid Chromatography. In vitro dissolution profiles showed that matrices agents favored a reservoir effect. Active metabolite Albendazole sulphoxide (ABZSO) or Ricobendazole (RBZ) plasma exposure measured in terms of area under concentration vs time curve (AUC) of all RBZ formulations was greater (p<0,05) when compared with that obtained for ABZ reference formulation. No statistical differences in AUC values were found among all RBZ formulations assayed (p>0.05). Nevertheless, RBZ-Cetyl alcohol formulation showed a statistical difference on its time peak concentration (p<0.05). In conclusion the results obtained in vitro do not correlate with those obtained in vivo, being this work useful to identify other matrices developers in RBZ-CR formulations.
Fil: Dib, Alicia. Universidad de la República; Uruguay
Fil: Paredes, Alejandro Javier. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Eliópulos, Natasha. Universidad de la República; Uruguay
Fil: Farias, Cristina Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Suárez, Gonzalo. Universidad de la República; Uruguay
Fil: Aldrovandi, Ariel. Universidad de la República; Uruguay
Fil: Palma, Santiago Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Allemandi, Daniel Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica. Universidad Nacional de Córdoba. Facultad de Ciencias Químicas. Unidad de Investigación y Desarrollo en Tecnología Farmacéutica; Argentina
Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
Fil: Sanchez Bruni, Sergio Fabian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina
description The aim of this study was to evaluate the influence of different matrices developers on the pharmacokinetic behavior of Ricobendazole (RBZ) controlled release (CR) formulations and test their correlation in vitro-in vivo, using one Albendazole (ABZ)-based and one RBZ-based immediate-release formulation as references. The main excipients used for CR formulations were Hydroxypropyl Methyl Cellulose, Cetyl Alcohol, Gelucire 50/02® and Alginic Acid. Pharmacotechnical quality control tests were successfully completed. Twelve parasite-free no pregnant dogs were randomly divided into six groups and received different treatments (single oral doses) using an incomplete block design (two phases) (n=4). Phase I: treatment "A" (ABZ-based immediate-release formulation [25 mg/kg]). Treatment "B" (RBZ-based immediate release formulation [20 mg/kg]) and treatments from "C" to "F" (CR formulations [20 mg/kg]). Phase II was performed after 21 days of washout period. Blood samples were collected over 48 h and analysed by UV High Performance Liquid Chromatography. In vitro dissolution profiles showed that matrices agents favored a reservoir effect. Active metabolite Albendazole sulphoxide (ABZSO) or Ricobendazole (RBZ) plasma exposure measured in terms of area under concentration vs time curve (AUC) of all RBZ formulations was greater (p<0,05) when compared with that obtained for ABZ reference formulation. No statistical differences in AUC values were found among all RBZ formulations assayed (p>0.05). Nevertheless, RBZ-Cetyl alcohol formulation showed a statistical difference on its time peak concentration (p<0.05). In conclusion the results obtained in vitro do not correlate with those obtained in vivo, being this work useful to identify other matrices developers in RBZ-CR formulations.
publishDate 2015
dc.date.none.fl_str_mv 2015-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/62956
Dib, Alicia ; Paredes, Alejandro Javier; Eliópulos, Natasha; Farias, Cristina Elena; Suárez, Gonzalo; et al.; Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs; OMICS International; Clinical & Experimental Pharmacology; 5; 6; 12-2015; 1-8
2161-1459
CONICET Digital
CONICET
url http://hdl.handle.net/11336/62956
identifier_str_mv Dib, Alicia ; Paredes, Alejandro Javier; Eliópulos, Natasha; Farias, Cristina Elena; Suárez, Gonzalo; et al.; Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs; OMICS International; Clinical & Experimental Pharmacology; 5; 6; 12-2015; 1-8
2161-1459
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4172/2161-1459.1000198
info:eu-repo/semantics/altIdentifier/url/https://www.omicsonline.org/open-access/pharmacokinetic-assessment-of-novel-controlled-release-formulations-ofricobendazole-intended-for-oral-administration-in-dogs-2161-1459-1000198.php?aid=64163
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv OMICS International
publisher.none.fl_str_mv OMICS International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613681960189952
score 13.070432

Publicaciones similares